{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:40Z","timestamp":1791347320675,"version":"4.3.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"DOI":"10.1093\/jac\/dku348","type":"journal-article","created":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T03:54:10Z","timestamp":1411185250000},"page":"225-232","source":"Crossref","is-referenced-by-count":23,"title":["Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship*"],"prefix":"10.1093","volume":"70","author":[{"given":"Nilesh B.","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindiya","family":"Meggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Barrail-Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilesh V.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e1dia","family":"Sitoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Vubil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nhadzombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Sitoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Del\u00e1rio","family":"Nhumaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odete","family":"Bule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1tia","family":"Cossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabete","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Samo","family":"Gudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu\u00e9","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ciaffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Sobry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Lugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avertino","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rouzioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,9,18]]},"reference":[{"key":"key\n\t\t\t\t20170425180922_DKU348C1","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170425180922_DKU348C2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.7196\/SAMJ.4621","article-title":"The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis","volume":"100","year":"2010","journal-title":"S Afr Med J"},{"key":"key\n\t\t\t\t20170425180922_DKU348C3","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170425180922_DKU348C4","author":"WHO"},{"key":"key\n\t\t\t\t20170425180922_DKU348C5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e328353b047","article-title":"Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals","volume":"26","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425180922_DKU348C6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa","volume":"14","year":"2009","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170425180922_DKU348C7","first-page":"389","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis","volume":"61","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425180922_DKU348C8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/505210","article-title":"Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin","volume":"43","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425180922_DKU348C9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170425180922_DKU348C10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation","volume":"38","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170425180922_DKU348C11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0962-8479(93)90032-S","article-title":"Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis","volume":"74","year":"1993","journal-title":"Tuber Lung Dis"},{"key":"key\n\t\t\t\t20170425180922_DKU348C12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7196\/SAMJ.6344","article-title":"The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care","volume":"103","year":"2013","journal-title":"S Afr Med J"},{"key":"key\n\t\t\t\t20170425180922_DKU348C13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170425180922_DKU348C14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0378-4347(00)00208-5","article-title":"Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma","volume":"742","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"key\n\t\t\t\t20170425180922_DKU348C15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00007691-200206000-00015","article-title":"High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma","volume":"24","year":"2002","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20170425180922_DKU348C16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200106150-00003","article-title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","volume":"15","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425180922_DKU348C17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425180922_DKU348C18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350801300414","article-title":"Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin","volume":"13","year":"2008","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170425180922_DKU348C19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/135965350701200406","article-title":"Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians","volume":"12","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170425180922_DKU348C20","first-page":"180","article-title":"Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin","volume":"66","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425180922_DKU348C21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/QAI.0b013e3181b0328f","article-title":"Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis","volume":"52","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170425180922_DKU348C22","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425180922_DKU348C23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/clpt.2010.172","article-title":"Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients","volume":"88","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170425180922_DKU348C24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-011-1166-5","article-title":"The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis","volume":"68","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170425180922_DKU348C25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study","volume":"57","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425180922_DKU348C26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jit466","article-title":"Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia","volume":"209","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170425180922_DKU348C27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study","volume":"12","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"key\n\t\t\t\t20170425180922_DKU348C28","doi-asserted-by":"crossref","first-page":"e40180","DOI":"10.1371\/journal.pone.0040180","article-title":"Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170425180922_DKU348C29","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425180922_DKU348C30","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1128\/AAC.02599-12","article-title":"Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients","volume":"57","journal-title":"Antimicrob Agents Chemother;"},{"key":"key\n\t\t\t\t20170425180922_DKU348C31","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425180922_DKU348C32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-7-8","article-title":"Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV\/TB co-infected Thai adults","volume":"7","year":"2010","journal-title":"AIDS Res Ther"},{"key":"key\n\t\t\t\t20170425180922_DKU348C33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20170425180922_DKU348C34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170425180922_DKU348C35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/FPC.0b013e32835a5af2","article-title":"Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians","volume":"22","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20170425180922_DKU348C36","first-page":"13","article-title":"Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population","volume":"20","year":"2013","journal-title":"Malays J Med Sci"},{"key":"key\n\t\t\t\t20170425180922_DKU348C37","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1128\/AAC.02294-12","article-title":"Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T18:52:36Z","timestamp":1746384756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dku348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,9,18]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku348","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,18]]}}}